<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03948724</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-2019-02</org_study_id>
    <nct_id>NCT03948724</nct_id>
  </id_info>
  <brief_title>Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology</brief_title>
  <acronym>EDHITO</acronym>
  <official_title>Randomized Controlled Trial Evaluating the Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this therapeutic education program is to reduce the apparition of immune-related
      Adverse Event with patients treated with ICI
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to highlight the impact of Patient Therapeutic Education (TPE) in oncology.
      TPE is an integral part of the care pathway for patients with a chronic pathology such as
      diabetes, asthma, chronic obstructive pulmonary disease, cardiovascular diseases requiring
      anticoagulants, haemophilia, renal failure, HIV infection, autoimmune diseases etc.... front
      of therapeutic progress, many cancers are now taken for a chronic disease.

      In oncology, TPE starts to grow. Indeed, TPE makes the patient more autonomous, which could
      reduce the occurrence and / or aggravation of some toxicities, improve the quality of life,
      the effectiveness of treatment and optimize health costs. Therefore, it is important to
      develop programme of therapeutic education in oncology.

      The toxicity of ICI is unusual and sometimes lethal. This toxicity must be recognized and
      managed quickly to maintain a satisfactory dose-intensity. TPE finds its place by raising
      awareness among patient to the occurrence of these toxicities.

      This randomized TPE versus standard care study project will assess the contribution of
      education in the management of severe toxicities. The investigators believe that changes in
      patient behaviour will reduce the number of toxicities ≥3 in the TPE arm.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2019</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the number of patients with at least one grade ≥ 3 immune-related Adverse Event (irAE) toxicity for 25 weeks after initiation of ICI treatment between both arm</measure>
    <time_frame>36 months</time_frame>
    <description>Measure of the number of patients with at least one immune-related Adverse Event (irAE) grade ≥ 3 (CTCAE v5.0) for 25 weeks following the beginning of ICI treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the toxicity of Immune Checkpoint Inhibitors (ICI)</measure>
    <time_frame>36 months</time_frame>
    <description>Description of immune-related Adverse Event of grade&gt; 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of ICI treatment received</measure>
    <time_frame>36 months</time_frame>
    <description>Description of each cycle of ICI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring the level of knowledge of patients related to the disease, the treatment and its side effects</measure>
    <time_frame>36 months</time_frame>
    <description>Measuring the level of knowledge of patients with a specific questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' quality of life assessment: Hospital Anxiety and Depression Scale</measure>
    <time_frame>36 months</time_frame>
    <description>quality of life evaluated with the Hospital Anxiety and Depression Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' quality of life assessment: questionnaire-C30</measure>
    <time_frame>36 months</time_frame>
    <description>quality of life evaluated with the Quality-of-life questionnaire-C30</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">411</enrollment>
  <condition>Therapeutic Patient Education</condition>
  <condition>Immune Checkpoint Inhibitors</condition>
  <condition>Melanoma</condition>
  <condition>Advanced Non-small Cell Lung Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Immune-related Adverse Event</condition>
  <arm_group>
    <arm_group_label>Therapeutic patient education</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient follow sessions the therapeutic patient education with manual therapy, therapeutic education, therapeutic exercize</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient receive usual informations</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Therapeutic education program</intervention_name>
    <description>Patient follow sessions the therapeutic patient education with manual therapy, therapeutic education, therapeutic exercize</description>
    <arm_group_label>Therapeutic patient education</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Usual Information</intervention_name>
    <description>Patient receive usual informations</description>
    <arm_group_label>Standard Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with Melanoma, Non-Small Cell Bronchial Cancer, renal cell carcinoma, Ca
             carcinomas of the upper airways to be treated with ICI

          -  Patient who has never received treatment by ICI

          -  Informed patient who signed his consent

          -  Age &gt; or = 18 years

          -  Social insurance

        Exclusion Criteria:

          -  Patient receiving corticosteroid or immunosuppressant 14 days before inclusion

          -  Immunocompromised patient

          -  Uncontrolled brain metastases

          -  Refusal to participate, patient protected by guardianship

          -  Patient unable to understand the study or unable to follow the education sessions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie Beaumont</last_name>
    <role>Principal Investigator</role>
    <affiliation>INSTITUT DE CANCEROLOGIE DE L'OUEST</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Virginie Berger, MD</last_name>
    <phone>+33 241352700</phone>
    <email>virginie.berger@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathalie Beaumont</last_name>
    <phone>+33 241352700</phone>
    <email>nathalie.beaumont@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Angers</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PIERRE BIGOT, MD</last_name>
      <email>pibigot@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Angers</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>YANNICK LECORRE, MD</last_name>
      <email>yalecorre@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle Bonnet, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre D'Oncologie Et de Radiotherapie 37</name>
      <address>
        <city>Chambray-lès-Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>PIERRE COMBE, md</last_name>
      <email>p.combre@cort37.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>REGINE CHEVRIER</last_name>
      <email>Regine.CHEVRIER@clermont.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chd Vendee</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SOPHIE LIMOUSIN</last_name>
      <email>charlotte.massuyeau@chd-vendee.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ALEXANDRA FORESTIER, MD</last_name>
      <email>a-forestier@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>63373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MAURICE PEROL, MD</last_name>
      <email>maurice.perol@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>CLAIRE LLAMBRICH-MOLINE</last_name>
      <email>clairellambrichmoline@curie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>LIONEL GEOFFROIS, MD</last_name>
      <email>l.geoffrois@nancy.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MARILENE GUILLET-LACAZE</last_name>
      <email>marilene.lacaze@gustave.roussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 10, 2019</study_first_submitted>
  <study_first_submitted_qc>May 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2019</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

